Table 4.
Response of Plasma Lipid and Coronary Atherosclerosis to Treatment with Fluvastatin According to Genotypes of rs2383206 SNP at the 9p21 Locus
| Genotypes | ||||
| GG | GA | AA | P | |
| A. Response of plasma lipids levels | ||||
| N = 165 | 51 | 97 | 17 | |
| % Change in total cholesterol | -14.7 ± 10.7 | -16.5 ± 14.9 | -15.4 ± 10.6 | 0.183* |
| % Change in LDL-C | -25.8 ± 13.8 | -26.1 ± 20.2 | -23.2 ± 14.5 | 0.040* |
| % Change in HDL-C | 9.2 ± 14.6 | 9.9 ± 16.1 | 6.7 ± 15.0 | 0.734 |
| % Change in Triglyceride | 9.6 ± 42.9 | 5.4 ± 36.0 | 5.1 ± 24.8 | 0.002* |
| % Change in apoB | -16.4 ± 14.0 | -16.9 ± 17.1 | -13.6 ± 11.6 | 0.737 |
| % Change in apo A1 | 8.1 ± 16.5 | 6.4 ± 22.0 | 4.5 ± 16.0 | 0.801 |
| B. Response of coronary atherosclerosis | ||||
| N = 147 | 46 | 84 | 17 | |
| New coronary lesions (mean) | 0.30 ± 0.47 | 0.25 ± 0.45 | 0.24 ± 0.44 | 0.768 |
| Subjects with new coronary lesions (%) | 14 (30.4) | 21 (25.0) | 4 (23.5) | 0.664 |
| New coronary occlusions (mean) | 0.04 ± 0.21 | 0.04 ± 0.19 | 0.0 ± 0.0 | 0.698 |
| Subjects with new coronary occlusions (%) | 2 (4.4) | 3 (3.7) | 0 (0) | 0.694 |
| Average final MLD (mm) | 1.54 ± 0.44 | 1.60 ± 0.47 | 1.76 ± 0.50 | 0.396 |
| Change in MLD (mm) | -0.04 ± 0.27 | -0.05 ± 0.26 | -0.01 ± 0.20 | 0.807 |
Abbreviations: m: meter; Kg: Kilogram; mmHg: millimeter mercury; mg/dl: milligram per deciliter; HDL-C: High-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; Apo A: apolipoprotein A; Apo B: apolipoprotein B; Apo C-III: apolipoprotein C3; MLD: minimal lumen diameter.